The Effect of Intra-anal Nifedipine, Used As Add-on to Conservative Therapy, on Pain in Patients With Anal Fissure

NCT ID: NCT02527109

Last Updated: 2018-10-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 339 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-05-31
• Study Completion Date: 2018-08-22

Brief Summary

The objective of the study is to examine the effect of Nifedipine, applied intra-anally through our drug delivery device, on rectal pain severity in anal fissure patients that are being managed with conservative treatment.

Detailed Description

This is a randomized, double-blinded study. All patients in the study will be treated with the conservative standard of care for anal fissure. Study medication will be used as an add-on to conservative therapy, and will consist of 3 groups:

1. Treatment Group 1- 12 mg of Nifedipine to be self-administered twice daily.

2. Treatment Group 2- 12 mg of Nifedipine to be self-administered once daily in the morning hours and placebo to be self-administered in the evening.

3. Placebo Group - Placebo to be self-administered twice daily. Approximately 330 subjects will participate in this study. A screening visit will be used to determine subject suitability for inclusion in the trial. Within one week of the screening visit, subjects who meet all inclusion criteria and none of the exclusion criteria will receive either Nifedipine 12 mg X2 a day (BID) (24 mg/day total) or Nifedipine 12 mg X1/day to be administered in the morning hours and a matching placebo X1/day to be administered in the evening hours (12 mg/day total) or a matching placebo X2 a day (BID) (0 mg/day total) for a period of 8 weeks. During this period, 4 study visits (at 0, 2, 5, and 8 weeks) will take place. Study medication and placebo will be administered BID (in the morning and in the evening). In addition to receiving study medication, subjects will be maintained on a conservative standard treatment for Anal Fissure: sitz baths, high fiber diet, stool softeners and plenty of fluids.

Upon completion of the treatment cycle, patients will be contacted by phone (at weeks 10, 13 and 16) and will be questioned about recurrent symptoms e.g. pain or bleeding.

Patients that:

1. Were enrolled to one of the investigational groups ,and completed the 8 weeks treatment period or discontinued treatment because the investigator deemed them as healed AND

2. Experience symptoms of recurrence AND ARE

3. Willing to participate in an open label extension will receive Nifedipine 12 mg X2 a day (BID) for a period of 8 weeks. During this period, 4 study visits (at 0, 2, 5, and 8 weeks from the start of retreatment) will take place.

Conditions

Chronic Anal Fissure

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Placebo

Intra-anal placebo administered BID.

Group Type: PLACEBO_COMPARATOR

Nifedipine

Intervention Type: DRUG

Nifedipine 12 mg/day

Intra-anal Nifedipine 12 mg administered OD.

Group Type: EXPERIMENTAL

Nifedipine

Intervention Type: DRUG

Nifedipine 24 mg/day

Intra-anal Nifedipine 12 mg administered BID.

Group Type: EXPERIMENTAL

Nifedipine

Intervention Type: DRUG

Interventions

Nifedipine

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Subjects meeting the following criteria will be eligible to participate in the trial:

1. Single anal fissure;

2. Signed written informed consent;

3. Male or female subjects 18 to 65 years of age inclusive;

4. Has chronic anal fissure defined as history of rectal pain at least three days a week for at least 6 weeks - or more AND at least one of the following:

• Sentinel skin tag
• Hypertrophied anal papilla
• Exposure of the underlying internal anal sphincter
• Anal cicatrisation

5. Visual analogue scale of average 24 hours rectal pain (VAS) of > 40 mm in screening visit

6. Capable of using the IVRS and able to adequately communicate comprehension of the IVRS questions to the investigator

7. If female, is non-lactating, has a negative urine pregnancy test result, and does not plan on becoming pregnant during the study, or not of childbearing potential (hysterectomy or tubal ligation at least 6 months prior to entry to the study or post-menopausal for 1 year); if of childbearing potential (including peri-menopausal women who have had a menstrual period within one year) must practice or be willing to continue to practice acceptable birth control from screening and until 1 week after the study medication has been discontinued.

Acceptable birth control includes :

• combined (estrogen and progestogen containing) hormonal contraception
• associated with inhibition of ovulation; oral OR intravaginal OR transdermal.
• progestogen-only hormonal contraception associated with inhibition of ovulation: oral OR injectable OR implantable.
• progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action
• intrauterine device (IUD)
• intrauterine hormone-releasing system ( IUS)
• bilateral tubal occlusion
• vasectomised partner
• sexual abstinence
• male or female condom with or without spermicide
• cap, diaphragm or sponge with spermicide

Exclusion Criteria

• Subjects are excluded from participation in the study if any of the following criteria apply:

1. Known allergy to Nifedipine

2. Unwilling to stop all other concomitant topical preparations applied in and around the anus from screening through the end of the study

3. Subfissure injection of botulinum toxin in the 3 months prior to screening.

4. Fissure resulting from inflammatory bowel disease, venereal disease, perianal psoriasis, immunodeficiency syndrome

5. Atypical fissure (occurs off the midline) in which secondary causes were not excluded.

6. Deemed by the investigator as anal fissure for which surgery is indicated

7. Anal abscess;

8. Grade 4 hemorrhoids

9. Fixed anal stenosis

10. Active or past history of cardiovascular or cerebrovascular disease including but not limited to angina pectoris, myocardial infarction, transient ischemic attacks/stroke, arrhythmia or ecg changes that requires medical treatment or deemed by the investigator as clinically significant, moderate to severe congestive heart failure, or cardiac valve abnormalities;

11. Type 1 diabetes mellitus

12. Insulin treated type 2 diabetes mellitus

13. Renal failure defined as a serum creatinine > 1.5 mg/dL (133 µmol/L) at screening

14. Liver disease defined as Aspartate aminotransferase (AST) or alanine aminotransferase(ALT) >2 X upper limit of normal at screening

15. Malignant disease within 3 years of screening

16. Has uncontrolled hypertension (sitting blood pressure >160/95 mmHg at screening)

17. Has hypotension (blood pressure lower than 90/60 mm Hg at screening)

18. History of chronic gastrointestinal disease such as Crohn's disease or ulcerative colitis

19. History of major rectal surgery

20. History of HIV, Hepatitis B, Hepatitis C

21. Has clinical laboratory test values (chemistry, hematology, or urinalysis) judged to be clinically significant by the investigator at screening;

22. Has used, in the last two weeks, drugs that may affect blood coagulation, such as Aspirin at a dose higher than 500 mg/day, Warfarin, Sintrom, Enoxaparin, Nadroparin, Heparin, Clopidogrel, Ticlopidine Rivaroxaban, Apixaban, Edoxaban

23. Is treated with drugs that may affect the anal sphincter:

1. Calcium channel blockers such as Nifedipine, Diltiazem or Verapamil

2. Nitroglycerin or nitrates

24. Has, upon physical examination, a rectal deformation or signs of rectal disease such as fistula, infection or space occupying lesion;

25. Participated in a clinical study in the last 30 days prior to screening.

26. Is an immediate family member of personnel directly affiliated with the study at the investigative site, or is personally directly affiliated with the study at the investigative site; or is employed or related to the Sponsor, CRO or investigator;

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

RDD Pharma Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

UMHAT "Sveti Georgi", Internal Consulting Department

Plovdiv, , Bulgaria

"Multiprofile Hospital for Active Treatment - Doverie" AD, Clinic of Gastroenterology

Sofia, , Bulgaria

II MHAT, Internal Clinic, Department of Gastroenterology

Sofia, , Bulgaria

MC Health BG EOOD

Sofia, , Bulgaria

Multiprofile Hospital for Active Treatment Lulin

Sofia, , Bulgaria

MC "New rehabilitation centre'' EOOD

Stara Zagora, , Bulgaria

"Multiprofile Regional Hospital for Active Treatment - Dr. St. Cherkezov" AD Department of Gastroenterology

Veliko Tarnovo, , Bulgaria

IMSP Spitalul Clinic Municipal Nr 1

Chisinau, , Moldova

IMSP Spitalul Clinic Municipal Nr 3 "Sfanta Treime"

Chisinau, , Moldova

IMSP Spitalul Clinic Republican

Chisinau, , Moldova

Med-Gastr Centrum Medyczne

Lodz, , Poland

Ambulatorium Medyczne Medical Hair & Esthetic

Lublin, , Poland

Centrum Innowacyjnych Terapii Sp. z o.o. Oddział w Piasecznie

Piaseczno, , Poland

NZOZ Specjalistyczne Centrum Medyczne Flebo

Wołomin, , Poland

Pelican Impex SRL

Oradea, Jud. Bihor, Romania

Institutul Regional de Gastroenterologie si Hepatologie "Prof. Dr. Octavian Fodor"

Cluj-Napoca, Jud. Cluj, Romania

IRGH

Cluj-Napoca, Jud. Cluj, Romania

Tvm Med Serv Srl

Cluj-Napoca, Jud. Cluj, Romania

SC Schnelbach Medical Care SRL

Ploieşti, Jud. Prahova, Romania

Spit. Clinic Judetean de Urgenta "Sf. Apostol Andrei" Constanta

Constanța, Judet Constanta, Romania

Dacmed SRL

Ploieşti, Prahova, Romania

Centrul Medical de Diagnostic si Tratament Ambulator Neomed SRL

Brasov, , Romania

Institutul Clinic Fundeni

Bucharest, , Romania

Centrul Medical Sfanta Vineri SRL

Bucharest, , Romania

Countries

Bulgaria; Moldova; Poland; Romania

Other Identifiers

RDD 110

Identifier Type: -

Identifier Source: org_study_id